Current trends in the pharmacological management of Chagas disease

Albercal, 2016, Discovery of novel polyamine analogs with anti-protozoal activity by computer guided drug repositioning, J. Comput. Aided Mol. Des., 305, 10.1007/s10822-016-9903-6 Andrews, 2014, Drug repurposing and human parasitic protozoan diseases, Int. J. Parasitol.: Drugs Drug Resist., 4, 95 Apt, 2013, Treatment of Chagas' disease with itraconazole: electrocardiographic and parasitological conditions after 20 years of follow-up, J. Antimicrob. Chemother., 2164, 10.1093/jac/dkt135 Bahia, 2012, Fexinidazole: a potential new drug candidate for Chagas disease, PLoS Neglected Trop. Dis., 1 Bahia, 2014, Antitrypanosomal activity of fexinidazole metabolites, potential new drug candidates for Chagas disease, Antimicrob. Agents Chemother., 4362, 10.1128/AAC.02754-13 Bastos, 2019, Chemical constituents of Anacardium occidentale as inhibitors of Trypanosoma cruzi sirtuins, Molecules, 24, 1299, 10.3390/molecules24071299 Benson, 1992, Rationally designed selective inhibitors of trypanothione reductase. Phenothiazines and related tricyclics as lead structures, Biochem. J., 286, 9, 10.1042/bj2860009 Bocchi, 2017, Chronic Chagas heart disease management: from etiology to cardiomyopathy treatment, J. Am. Coll. Cardiol., 1510, 10.1016/j.jacc.2017.08.004 Boiani, 2010, Mode of action of Nifurtimox and N-oxide-containing heterocycles against Trypanosoma cruzi: is oxidative stress involved?, Biochem. Pharmacol., 79, 1736, 10.1016/j.bcp.2010.02.009 Branquinho, 2014, Sesquiterpene lactone in nanostructured parenteral dosage form is efficacious in experimental Chagas disease, Antimicrob. Agents Chemother., 2067, 10.1128/AAC.00617-13 Coura, 2002, A critical review on Chagas disease chemotherapy, Memórias do Inst. Oswaldo Cruz, 97, 3, 10.1590/S0074-02762002000100001 Coura, 2009, Epidemiology, control and surveillance of Chagas disease: 100 years after its discovery, Mem. Inst. Oswaldo Cruz, 31, 40 Da Nóbrega, 2014, Mortality due to Chagas disease in Brazil according to a specific cause, Am. J. Trop. Med. Hyg., 528, 10.4269/ajtmh.13-0574 Da Silva, 2016, In vivo and in vitro auranofin activity, against Trypanosoma cruzi: possible new uses for an old drug, Exp. Parasitol., 189, 10.1016/j.exppara.2015.05.012 Da Silva, 2012, Preclinical monitoring of drug association in experimental chemotherapy of Chagas' disease by a new HPLC-UV method, Antimicrob. Agents Chemother., 3444 De Araújo, 2019, Imidazole derivatives as promising agents for the treatment of Chagas disease, Antimicrob. Agents Chemother., 10.1128/AAC.02156-18 Moreira, 2013, Effect of thiazolidine LPSF SF29 on the growth and morphology of Trypanosoma cruzi, Int. J. Antimicrob. Agents, 41, 183, 10.1016/j.ijantimicag.2012.09.018 Deeks, 2019, Fexinidazole: first global approval, Drugs Dias, 2009, 2444 Dias, 2016, 7 de Figueiredo Diniz, 2013, Benznidazole and posaconazole in experimental Chagas disease: positive interaction in concomitant and sequential treatments, PLoS Neglected Trop. Dis., 1 Do Carmo, 2019, Cordycepin (3′-deoxyadenosine) and pentostatin (deoxycoformycin) against Trypanosoma cruzi, Exp. Parasitol., 199, 47, 10.1016/j.exppara.2019.02.016 Fauro, 2013, Use of clomipramine as chemotherapy of the chronic phase of Chagas disease, Parasitology, 917, 10.1017/S0031182013000103 Ferreira, 2018, Efficacy of sertraline against Trypanosoma cruzi: an in vitro and in silico study, J. Venom. Anim. Toxins Incl. Trop. Dis., 24, 10.1186/s40409-018-0165-8 Ferreira, 2016, Drug repositioning approaches to parasitic diseases: a medicinal chemistry perspective, Drug Discov. Today, 21, 1699, 10.1016/j.drudis.2016.06.021 Fracasso, 2019, Effects of resveratrol on the differentiation fate of neural progenitor cells of mouse embryos infected with Trypanosoma cruzi, Microb. Pathog., 10.1016/j.micpath.2019.04.040 Francisco, 2015, Limited ability of posaconazole to cure both acute and chronic trypanosoma cruzi infections revealed by highly sensitive in vivo imaging, Antimicrob. Agents Chemother., 59, 4653, 10.1128/AAC.00520-15 Francisco, 2016, Nitroheterocyclic drugs cure experimental Trypanosoma cruzi infections more effectively in the chronic stage than in the acute stage, Sci. Rep., 6, 10.1038/srep35351 García-Huertas, 2018, Activity in vitro and in vivo against Trypanosoma cruzi of a furofuran lignan isolated from Piper jericoense, Exp. Parasitol., 189, 34, 10.1016/j.exppara.2018.04.009 González-Herrera, 2017, Simvastatin attenuates endothelial activation through 15-epi-lipoxin A4 production in murine chronic Chagas cardiomyopathy, Antimicrob. Agents Chemother., 1 Guedes da Silva, 2019, Successful aspects of the Co-administration of sterol 14α-demethylase inhibitor VFV and benznidazole in experimental mouse models of Chagas disease caused by the drug-resistant strain of Trypanosoma cruzi, ACS Infect. Dis., 10.1021/acsinfecdis.8b00253 Hall, 2011, Nifurtimox activation by trypanosomal type I nitroreductases generates cytotoxic nitrile metabolites, J. Biol. Chem., 286, 13088, 10.1074/jbc.M111.230847 Hargrove, 2013, Complexes of Trypanosoma cruzi sterol 14α-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease, J. Biol. Chem., 31602, 10.1074/jbc.M113.497990 Hernández, 2018, Curcumin exerts anti-inflammatory and vasoprotective effects through amelioration of NFAT-dependent endothelin-1 production in mice with acute Chagas cardiomyopathy, Memórias do Inst. Oswaldo Cruz, 113 Kratz, 2018, Clinical and pharmacological profile of benznidazole for treatment of Chagas disease, Expert Rev. Clin. Pharmacol. Khare, 2016, Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness, Nature, 229, 10.1038/nature19339 Krieger, 2002, Trypanosomes lacking trypanothione reductase are avirulent and show increased sensitivity to oxidative stress, Mol. Microbiol., 35, 542, 10.1046/j.1365-2958.2000.01721.x Konduri, 2017, Genetic adjuvantation of a cell-based therapeutic vaccine for amelioration of chagasic cardiomyopathy, Infect. Immun., 85, 10.1128/IAI.00127-17 Lazarin-Bidóia, 2013, Further evidence of the trypanocidal action of eupomatenoid-5: confirmation of involvement of reactive oxygen species and mitochondria owing to a reduction in trypanothione reductase activity, Free Radic. Biol. Med., 60, 17, 10.1016/j.freeradbiomed.2013.01.008 Lourenço, 2018, Evaluation of in vitro anti-Trypanosoma cruzi activity of medications benznidazole, amiodarone hydrochloride, and their combination, Rev. Soc. Bras. Med. Trop., 51, 52, 10.1590/0037-8682-0285-2017 Maluf, 2013, A pharmacophore-based virtual screening approach for the discovery of Trypanosoma cruzi GAPDH inhibitors, Future Med. Chem., 5, 2019, 10.4155/fmc.13.166 Martín-Escolano, 2019, Insights into Chagas treatment based on the potential of bacteriocin AS-48, Int. J. Parasitol.: Drugs Drug Resist., 10, 1 Martins, 2015, Benznidazole/itraconazole combination treatment enhances anti-Trypanosoma cruzi activity in experimental Chagas disease, PLoS One, 1 Mejia, 2012, Benznidazole-resistance in Trypanosoma cruzi is a readily acquired trait that can arise independently in a single population, J. Infect. Dis., 206, 220, 10.1093/infdis/jis331 Melo-Filho, 2019, Discovery of new potent hits against intracellular Trypanosoma cruzi by QSAR-based virtual screening, Eur. J. Med. Chem., 10.1016/j.ejmech.2018.11.062 Mendonça, 2018, Relevance of trypanothione reductase inhibitors on trypanosoma cruzi infection: a systematic review, meta-analysis, and in silico integrated approach, Oxidative Med. Cell. Longev., 2018, 1, 10.1155/2018/8676578 Miana, 2019, Design, synthesis and molecular docking studies of novel N-arylsulfonyl-benzimidazoles with anti-Trypanosoma cruzi activity, Eur. J. Med. Chem., 165, 1, 10.1016/j.ejmech.2019.01.013 Molina, 2014, Randomized trial of posaconazole and benznidazole for chronic Chagas' disease, N. Engl. J. Med., 1899, 10.1056/NEJMoa1313122 Morillo, 2015, Randomized trial of benznidazole for chronic Chagas' cardiomyopathy, N. Engl. J. Med., 1295, 10.1056/NEJMoa1507574 Oliveira, 2017, Risk factors for treatment interruption and severe adverse effects to benznidazole in adult patients with Chagas disease. 1-13, PLoS One, 10.1371/journal.pone.0185033 Paixão, 2019, In vitro anti-Trypanosoma cruzi activity of ternary copper (II) complexes and in vivo evaluation of the most promising complex, Biomed. Pharmacother., 109, 157, 10.1016/j.biopha.2018.10.057 Papadopoulou, 2015, Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agents, J. Med. Chem., 1307, 10.1021/jm5015742 Perez-Mazliah, 2012, Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study, J. Antimicrob. Chemother., 424 Pérez-Molina, 2018, Chagas disease, The Lancet, 391, 82, 10.1016/S0140-6736(17)31612-4 Providello, 2018, Role of ascorbic acid as supporting in the therapeutic of Chagas disease: benefits in the association with low dose of benznidazole, AAC (Antimicrob. Agents Chemother.), 10.1128/AAC.00514-18 Rial, 2018, Experimental combination therapy using low doses of benznidazole and allopurinol in mouse models of Trypanosoma cruzi chronic infection, Parasitology, 1 Rocha Simões-Silva, 2019, Impact of levamisole in co-administration with benznidazole on experimental Chagas disease, Parasitology, 1 Rogers, 2012, Novel cruzain inhibitors for the treatment of Chagas' disease, Chem. Biol. Drug Des., 398, 10.1111/j.1747-0285.2012.01416.x Salas-Sarduy, 2017, Novel scaffolds for inhibition of Cruzipain identified from high through put screening of anti kinetoplastid chemical boxes, Nature, 1 Sales Junior, 2017, Experimental and clinical treatment of Chagas disease: a review, Am. J. Trop. Med. Hyg., 97, 1289, 10.4269/ajtmh.16-0761 Sbaraglini, 2016, Novel cruzipain inhibitors for the chemotherapy of chronic Chagas disease, Int. J. Antimicrob. Agents, 91, 10.1016/j.ijantimicag.2016.02.018 Scarim, 2018, Hydroxymethylnitrofurazone treatment in indeterminate form of chronic Chagas disease: reduced intensity of tissue parasitism and inflammation-A histopathological study, Int. J. Exp. Pathol., 10.1111/iep.12289 Scarim, 2018, Current advances in drug discovery for Chagas disease, Eur. J. Med. Chem., 155, 824, 10.1016/j.ejmech.2018.06.040 Simões-Silva, 2019, Repurposing strategies for Chagas disease therapy: the effect of imatinib and derivatives against Trypanosoma cruzi, Parasitology, 1 Sobrinho, 2009, Chagas's disease: 100 years from its Discovery, Rev. Bras. Ciencias Farm., 283 Sobrinho, 2007, Delineamento de alternativas terapêuticas para o tratamento da doença de Chagas, J. Trop. Pathol., 103 de Nazaré Correia Soeiro, 2013, In VitroandIn VivoStudies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi, Antimicrob. Agents Chemother., 4151, 10.1128/AAC.00070-13 Strauss, 2013, Clomipramine and benznidazole association for the treatment of acute experimental Trypanosoma cruzi infection, Parasitol. Int., 293, 10.1016/j.parint.2013.02.004 Strauss, 2018, In vitro and in vivo drug combination for the treatment of Trypanosoma cruzi infection: a multivariate approach, Exp. Parasitol., 189, 19, 10.1016/j.exppara.2018.04.016 Sülsen, 2016, Mode of action of the sesquiterpene lactones psilostachyin and psilostachyin C on Trypanosoma cruzi, PLoS One, 1 Sülsen, 2019, Activity of estafietin and analogues on Trypanosoma cruzi and Leishmania braziliensis, Molecules, 1 Torrico, 2018, Treatment of adult chronic indeterminate Chagas disease with benznidazole and three E1224 dosing regimens: a proof-of-concept, randomised, placebo-controlled trial, Lancet Infect. Dis., 18, 419, 10.1016/S1473-3099(17)30538-8 Valle-Reyes, 2017, Antiprotozoal drug nitazoxanide enhances parasitemia, tissue lesions and mortality caused by Trypanosoma cruzi in murine model, Exp. Parasitol., 44, 10.1016/j.exppara.2016.12.013 Vilar-Pereira, 2016, Resveratrol reverses functional Chagas heart disease in mice, PLoS Pathog., 1 Villalta, 2013, VNI cures acute and chronic experimental Chagas disease, J. Infect. Dis., 504, 511 Villanueva-Lizama, 2018, Trypanosoma cruzi vaccine candidate antigens Tc24 and TSA-1 recall memory immune response associated with HLA-A and -B super types in Chagasic chronic patients from Mexico, PLoS Neglected Trop. Dis., 1 Watson, 2019, A pharmacokinetic-pharmacodynamic assessment of the hepatic and bone-marrow toxicities of the new trypanoside fexinidazole, Antimicrob. Agents Chemother., 10.1128/AAC.02515-18 Wilkinson, 2008, A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes, Proc. Natl. Acad. Sci., 105, 5022, 10.1073/pnas.0711014105 World Health Organization, 2018